Form 4: Pfizer CEO Acquires Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, acquired 26 phantom stock units through a deferred compensation plan.

Summary

• Albert Bourla, Chairman & CEO of Pfizer Inc. (PFE), acquired 26 phantom stock units.
• The transaction occurred on July 31, 2025.
• Each unit represents one phantom share of common stock.
• The units were acquired at a price of $23.29 per unit.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Following this acquisition, Bourla beneficially owns 731,620 phantom stock units.
• The units are settled in cash following separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Sentiment

Score: 6

Explanation: The acquisition of phantom stock units by the CEO is a positive signal of continued alignment with shareholder interests, although it is a routine transaction under a deferred compensation plan rather than an open market purchase, limiting its direct market impact.

Positives

• Chairman & CEO Albert Bourla acquired additional phantom stock units, aligning his interests with shareholder value.
• The acquisition was part of a deferred compensation plan, indicating a structured long-term incentive for executive compensation.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This is a routine insider transaction related to executive compensation, which is a common practice across various industries to align management incentives with company performance and shareholder interests.

Stakeholder Impact

• Shareholders: The CEO's increased phantom stock ownership aligns his interests with shareholder value, as these units are tied to the company's common stock performance.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by Pfizer's CEO as part of a deferred compensation plan. While it indicates continued alignment of management's interests with shareholders, it is not an open market purchase and does not provide new fundamental information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions.

Keywords

Pfizer, PFE, Albert Bourla, insider transaction, Form 4, phantom stock, deferred compensation, CEO, stock acquisition